{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:35Z","timestamp":1780987955094,"version":"3.54.1"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370198"],"award-info":[{"award-number":["82370198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ALK\u2010positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare subtype of peripheral T\u2010cell lymphoma with traditionally favorable prognosis. The introduction of brentuximab vedotin (BV) has significantly impacted treatment outcomes, but the long\u2010term survival trends and predictive factors for this population remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 1548 patients diagnosed with ALK+ ALCL between 2004 and 2017 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were categorized into two eras: pre\u2013BV (2004\u20132010,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009795) and post\u2013BV (2011\u20132017,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009753). Overall survival (OS) was compared between eras. A random survival forest (RSF) model was constructed to identify prognostic factors and stratify survival risk in the post\u2013BV cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      OS significantly improved in the post\u2013BV era (HR\u2009=\u20090.68, 95% CI: 0.58\u20130.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the 5\u2010year OS increasing from 59.3% to 72.3%. The RSF model identified age, Ann Arbor stage, primary site, B symptoms, and radiotherapy as key prognostic factors, showing good discrimination with C\u2010indices of 0.775 (training cohort) and 0.728 (testing cohort). Notably, radiotherapy was found to be a protective factor. The model effectively stratified patients into high\u2010risk (5\u2010year OS: 49.3%) and low\u2010risk (86.0%) groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The introduction of BV has significantly improved real\u2010world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71695","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:28:23Z","timestamp":1773030503000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival Trends and Prognostic Modeling in\n                    <scp>ALK<\/scp>\n                    \u2010Positive Anaplastic Large Cell Lymphoma: A Population\u2010Based Study in the Brentuximab Vedotin Era"],"prefix":"10.1002","volume":"15","author":[{"given":"Qiuyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213512"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101444"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02712-8"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3233"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.04.013"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567461"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0118"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15801"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0198"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-023-00488-2"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14740"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014745"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17896"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13804"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065664"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15859"},{"issue":"1","key":"e_1_2_13_32_1","article-title":"Evaluation of the NCCN\u2010IPI as a Prognostic Tool in PTCLs","volume":"130","author":"Ellin F.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009806"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001581"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.07.011"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.006"},{"issue":"4","key":"e_1_2_13_38_1","first-page":"1163","article-title":"Outcome of Combined Modality Treatment in First\u2010Line for Stage I\u2010E Peripheral T\u2010Cell Lymphoma; a Nationwide Population\u2010Based Cohort Study From The Netherlands","volume":"109","author":"Meeuwes F. O.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4830"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00272"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5479"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01080-1"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00356-z"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:47:50Z","timestamp":1777614470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cam4.71695"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71695","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71695"}}